May

Rapid Flu Tests May Prove Especially Helpful This Season

On October 5, Chiron Corporation notified the CDC that none of its influenza vaccine (Fluvirin) would be available for distribution in the United States for the current influenza season. In the wake of this sudden removal of nearly half of the anticipated American vaccine supply, medical officials and the general public have grown increasingly alarmed about the scarcity of vaccine and the ris...

Antibiotics Don't Prevent Future Urinary Tract Infections, May Cause Resistance in Future Infections

PHILADELPHIA, July 10, 2007 /PRNewswire-USNewswire/ -- After afirst childhood urinary tract infection (UTI), daily antibioticsmay not prevent another such infection, and may actually increasethe risk that the next urinary tract infection is caused byresistant bacteria, according to a new study in the July 11 issueof the Journal of the American Medical Association. In the first larg...

Samaritan's Alzheimer's Drug Caprospinol Suggests Brain May be Able to Heal From Alzheimer's Disease

Animal Study Confirms Caprospinol's (SP-233) Ability to Clear BrainPlaque and Empower Rat Brain Cells to Recover Memory Function In Vivo 'Proof of Concept' Study Proposes Direct CorrelationBetween Removing Beta Amyloid Plaque and Memory Recovery LAS VEGAS, July 10, 2007 (PRIME NEWSWIRE) -- SamaritanPharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs,is ple...

Mayo Clinic News Release: Mayo Clinic-led Study Improves Breast Cancer Risk Prediction in Women with Atypia

ROCHESTER, Minn., July 2, 2007-Women with at least three sites ofcellular atypia in breast tissue are nearly eight times more likelythan average women to develop breast cancer, according to findingsof a Mayo Clinic Cancer Center led study of women with atypicalhyperplasia. The findings are published in the July 1 issue of theJournal of Clinical Oncology. Several previous studies have show...

Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers

WASHINGTON, January 29, 2007 /PRNewswire-USNewswire/ -- RearAdmiral Timothy Ziemer (U.S. Navy, retired), the President'sMalaria Coordinator, announced his intent to name Dr. BernardNahlen to serve as Deputy Coordinator of the President's MalariaInitiative (PMI). Dr. Nahlen is a Commissioned Officer in the U.S.Public Heath Service and has most recently served as SeniorAdvisor, Monitoring...

New Study in Journal of Pediatrics Suggests Synagis (Palivizumab) May Reduce Subsequent Recurrent Wheezing in Preterm Infants

Prophylaxis with Synagis Decreases Incidence of Recurrent Wheeze byAlmost Half ABBOTT PARK, Ill. and GAITHERSBURG, Md., June 29, 2007/PRNewswire-FirstCall/ -- Abbott and MedImmune today announcedresults of a new study, published in the July issue of Journal ofPediatrics, showing that treatment with Synagis(R) (palivizumab)may reduce recurrent wheezing in premature infants by almosthalf.<...

Three Studies Suggest Abbott's Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis

One Groundbreaking Study Showed 11 Percent Fewer RA PatientsReported Job Loss When Treated With HUMIRA Combination TherapyCompared to Methotrexate Alone BARCELONA, Spain, June 15, 2007 /PRNewswire-FirstCall/ --Rheumatoid arthritis (RA) is one of the most common causes ofdisability in the Western world. New data released today show thatrheumatoid arthritis (RA) patients treated with Abbott...

Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimer's ConferenceCurrent Flurizan Phase 3 Study Design May Demonstrate Disease Modification

SALT LAKE CITY, UT, June 11, 2007 (MARKET WIRE via COMTEX NewsNetwork) -- Myriad Genetics, Inc. (NASDAQ: MYGN) (<a target="_blank" href="http://www.myriad.com/">www.myriad.com )announced today that it presented a mathematical comparison of a"Staggered Start" and a "Randomized Withdrawal" clinical trialdesign with a "Natural History Staggered Start" clinical trialdesign at the Alzheime...

Treating Heart Disease Risk Factors May Slow Alzheimer's Disease Progression

- Late Life Weight Loss and "Motivational Reserve" May Also AffectAlzheimer's Risk - WASHINGTON, June 10, 2007 /PRNewswire-USNewswire/ -- A new studysuggests that treating risk factors for heart disease and stroke,such as high blood pressure and diabetes, may slow the progressionof Alzheimer's disease, according to research reported today at the2nd Alzheimer's Association International Co...

Antidepressant Use May Boost Fracture Risk, From Harvard Women's Health Watch

BOSTON, May 29, 2007 /PRNewswire-USNewswire/ -- Evidence isaccumulating that depression is a risk factor for osteoporosis,reports the June 2007 issue of Harvard Women's Health Watch. Arecent study found that people ages 50 and over who regularly tookantidepressants called selective serotonin reuptake inhibitors(SSRIs) had double the rate of fractures as people not using suchmedications....

Preclinical Study Finds Protease Inhibitor-Resistant HIV May Have Reduced Potential to Develop Resistance to Panacos' Bevirimat

WATERTOWN, Mass.--(BUSINESS WIRE)--May 29, 2007 - PanacosPharmaceuticals, Inc. (NASDAQ:PANC), a biotechnology companydedicated to developing the next generation of antiviraltherapeutic products, today announced the results of a new studyindicating that HIV resistant to Protease Inhibitors (PI) may havereduced potential for the development of resistance to the HIVmaturation inhibitor bevirim...

Enzo Biochem Individualized Oral Immune Regulation Therapy May Be Effective Approach to Treating Crohn's Disease

WASHINGTON--(BUSINESS WIRE)--May 22, 2007 - Alequel(TM), anindividualized oral immune regulation preparation, may be aneffective treatment for moderate-to-severe Crohn's disease. Interimdata from two ongoing double-blind, placebo controlled Phase IIstudies suggest that this investigational approach induced goodclinical remissions and improved patients' quality of life comparedto placebo. Me...

New Study Demonstrates that Lubiprostone May Improve Symptom Relief Rates in Adults with Irritable Bowel Syndrome with Constipation (IBS-C)

WASHINGTON, May 21, 2007 /PRNewswire/ -- A new studydemonstrated that the active ingredient in Amitiza (lubiprostone),given 8 mcg twice a day, may improve symptom relief rates in adultswith irritable bowel syndrome with constipation (IBS-C). Theseresults were presented as a late-breaker at Digestive Disease Week2007, the largest annual international meeting of digestive diseasespecialist...

Data Suggest that Pegasys May be an Option in Hepatitis C Patients Unable to Tolerate Peg-Intron

WASHINGTON--(BUSINESS WIRE)--May 21, 2007 - Roche today announcedresults of a small study demonstrating that all patients whodiscontinued treatment with Peg-Intron(R) (peginterferon alfa-2b)and ribavirin due to adverse events within the first 12 weeks, wereable to complete 12 weeks of treatment with PEGASYS(R)(peginterferon alfa-2a) and ribavirin. Furthermore, 92 percent ofthese patients we...

Clinical Trial Data for Perforomist Inhalation Solution to be Presented at ATS on May 20, 2007

-- Data from Phase III pivotal trial demonstrate safety andefficacy of first FDA-approved nebulized formoterol fumarate forpatients with moderate to severe COPD -- NAPA, Calif., May 16, 2007 /PRNewswire/ -- Dey, L.P. announcedthat two clinical data presentations will be given at theInternational Conference of the American Thoracic Society (ATS) onSunday, May 20, at the Moscone Center in S...

Global Rabies Treatment May be Possible with NanoViricides Drugs

WEST HAVEN, Conn.--(BUSINESS WIRE)--May 14, 2007 - NanoViricides,Inc. (Pink Sheets: NNVC) discussed today the results of recentanimal studies against rabies that were presented along with thesuccessful BSL3 in vitro studies against a Clade 2 H5N1 virus atthe 23rd Annual Symposium of the Pan American Society for ClinicalVirology in Tampa, FL, on Wednesday, May 2. (Pan American Societyfor Cli...

Data Show FluMist May Reduce Seasonal Influenza Burden Among Children in School, Daycare Settings

New Economic Analyses of School and Daycare Study Outcomes SuggestVaccinating Against Influenza May Produce Cost Savings forCommunity at Large TORONTO, May 08, 2007 /PRNewswire-FirstCall/ -- MedImmune, Inc.announced today research results showing that use of FluMist(R)(Influenza Virus Vaccine Live, Intranasal) in daycare and schoolsettings may help reduce the burden of seasona...

Cobalis Expects to Report Phase III Top-Line Results in May

IRVINE, Calif.--(BUSINESS WIRE)--Apr 30, 2007 - Cobalis Corp. (OTCBB: CLSC), a pharmaceutical development company specializing inanti-allergy medications, today announced it has been informed byits independent contract research organization that it would needmore time to combine Cobalis' three locked data bases into a singledatabase before un-blinding and conducting the statistical analysis...

Aeolus Pharmaceuticals' AEOL 10113 May Play an Important Role Regulating the Oxidative Damage Induced by Ionizing Radiation

LAGUNA NIGUEL, Calif.--(BUSINESS WIRE)--Apr 23, 2007 - AeolusPharmaceuticals, Inc. (OTCBB:AOLS) announced the presentation ofdata by researchers at Loma Linda University Medical Center showingthat one of the Company's metalloporphyrin antioxidants, AEOL10113, may play an important role regulating the oxidative damageinduced by ionizing radiation. Radiation therapy is used alone or in comb...

MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases

- Preclinical Data Support Rationale for Targeting Pro-InflammatoryProtein - GAITHERSBURG, Md., April 18, 2007 /PRNewswire-FirstCall/ --MedImmune, Inc. today announced the publication of preclinicalstudy data demonstrating a role for high mobility group boxprotein-1 (HMGB1), a nuclear DNA-binding protein, in the pathologyof systemic autoimmune diseases such as systemic lupuserythematosus...

Novel Human Tissue Transgenic Cancer Model May Offer Significant Advance Toward Accurately Modeling Human Cancer

LOS ANGELES & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 18, 2007 -AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused onthe discovery and development of novel, targeted cancer medicines,presented today findings from its novel human-in-mouse (HIM) tissuetransgenic cancer model system, in which AVEO successfully createdinvasive human tumors that develop over time in mice from prim...

New Data Show Early Non-Response to Antipsychotic Treatment May Be Strong Predictor of Subsequent Non-Response for People with Schizophrenia

Findings indicate early non-responders unlikely to subsequentlyrespond, have substantially more treatment costs, and may benefitfrom earlier change in treatment strategy COLORADO SPRINGS, Colo., April 03, 2007 /PRNewswire-FirstCall/-- New data presented at the 2007 International Congress onSchizophrenia Research (ICOSR) suggest that antipsychotic drugresponse be assessed earlier than is p...

CSL Therapy That Mimics “Good” Cholesterol May Reduce Plaque Volume in Coronary Arteries

VICTORIA, Australia, March 27, 2007--CSL Limitedtoday announced results from a study published in the Journal ofthe American Medical Association that suggest infusions of a novelnew drug, CSL-111, to acutely raise HDL (“good”cholesterol) levels, may reduce the amount of plaque in thecoronary arteries of patients with a recent episode of acutecoronary syndrome (AC...

Curecumin May Be an Effective Treatment for Lung Cancer

MAUI, Hawaii, March 27, 2007 /PRNewswire-FirstCall/ -- BioponicPhytoceuticals, Inc. ("Bioponic" or "the Company") today announcedthat its Curecumin(TM) (a Bioresonant Phytotherapeutic(R) form ofTurmeric containing curcumin in a liquid nasal delivery system) maybe an important treatment for Lung Cancer. In a recent study published in Science Direct, "Induction ofApoptosis in Human L...

CSL Therapy That Mimics 'Good' Cholesterol May Reduce Plaque Volume in Coronary Arteries

NEW ORLEANS, March 26, 2007 /PRNewswire/ -- CSL Limited todayannounced results from a study published in the Journal of theAmerican Medical Association that suggest infusions of a novel newdrug, CSL-111, to acutely raise HDL ("good" cholesterol) levels,may reduce the amount of plaque in the coronary arteries ofpatients with a recent episode of acute coronary syndrome(ACS). ACS is...